Erythropoietin reduces the expression of myostatin in mdx dystrophic mice

Brazilian Journal of Medical and Biological Research

D. Feder¹  M. Rugollini¹  A. Santomauro Jr¹  L.p. Oliveira¹  V.p. Lioi¹  R. Dos Santos¹  L.g. Ferreira¹  M.t. Nunes¹  M.h. Carvalho¹  P.o. Delgado¹  A.a.s. Carvalho¹  F.l.a. Fonseca¹ 

关键词: Muscular dystrophy;    Erythropoietin;    Myostatin;    Skeletal muscle;    Quadriceps;   

DOI  :  10.1590/1414-431X20143858

来源: SciELO

【 摘 要 】

Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles. Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. In this study, we tested the possible therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α) was determined by quantitative real time polymerase chain reaction. Myostatin expression was significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO=0.60±0.11, control=1.07±0.11). On the other hand, rhEPO had no significant effect on the expression of TGF-β1 (rhEPO=0.95±0.14, control=1.05±0.16) and TNF-α (rhEPO=0.73±0.20, control=1.01±0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License